Daniel A. Erlanson

6.1k citations

50 papers · 4.4k indexed · 1 hit paper · h-index 27

Impact in

Computational Theory and Mathematics top 0.2%
- Computational Drug Discovery Methods
Molecular Biology top 2%
- Chemical Synthesis and Analysis
- Protein Structure and Dynamics
- Protein Tyrosine Phosphatases
- Protein Degradation and Inhibitors

Papers in

Computational Theory and Mathematics 18
- Computational Drug Discovery Methods 18
Organic Chemistry 17
- Click Chemistry and Applications 15

Co-authors: Wolfgang Jahnke Robert S. McDowell Thomas O’Brien James A. Wells Andrew C. Braisted Harren Jhoti Roderick E. Hubbard Stephen W. Fesik
Journals: Journal of Medicinal Chemistry (14 papers)Proceedings of the National Academy of Sciences (3 papers)Journal of the American Chemical Society (3 papers)Nature Communications (2 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)
Partner nations: United States Switzerland Netherlands

In The Last Decade

Daniel A. Erlanson

48 papers receiving 4.2k citations

Hit Papers

align trajectories log scale

Twenty years on: the impact of fragments on drug discovery 2016 · 684 citations

Peers

Countries citing papers authored by Daniel A. Erlanson

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Erlanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Erlanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Erlanson more than expected).

Fields of papers citing papers by Daniel A. Erlanson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Erlanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Erlanson. The network helps show where Daniel A. Erlanson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Daniel A. Erlanson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel A. Erlanson Line = papers co-authored together Daniel A. Erlanson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation Structure ·江声皖, Alexander G. Cioffi, DARIO MICCOLI, Yi Lin, Michael B. Shaghafi, Courtney M. Daczkowski, Johannes C. Hermann, Robert A. Everley, Richard M. Neve, Daniel A. Erlanson, Kevin R. Webster, Vikram M. Narayan, Weiru Wang	2025	1
2	A practical method for determining the rate of covalent modification of fragments and leads Nature Communications ·Thai Duy Vo, Jorge Cubides Camacho, Mayra Muné-Jiménez, Т.О. Разумова, Daniel A. Erlanson, Robert A. Everley	2025	0
3	Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy Cell Reports Medicine ·Rubén Rodríguez, Anne C. Hergarden, Kéba Mbaye, Ryan Keith Petit, 将弥真崎, Tanja Tašner, Teresa Tang, A. R. Patton, Craig R. Lee, Asmita Pant, Daniel A. Erlanson, Johan Enquist, Emily M. Irvine, Liu Run-yong, Julia Tonioli da Silva, Stig K. Hansen, Jian Luo, Manu V. Chakravarthy	2025	2
4	Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective Journal of Medicinal Chemistry ·王佴, Kenta Arai, Michelle R. Arkin, Daniel A. Erlanson, Iwan J. P. de Esch, I. Kravchenko, Stephen W. Fesik, Wolfgang Jahnke, Christopher N. Johnson, M. SCHROEDER	2025	0
5	Where and how to house big data on small fragments Nature Communications ·Daniel A. Erlanson, S.K. Burley, D. Fearon, James S. Fraser, Dale F. Kreitler, Maria Cristina Nonato, Naoki Sakai, J. Wollenhaupt, M.S. Weiss	2025	4
6	Targeting mutant KRAS Current Opinion in Chemical Biology ·Daniel A. Erlanson, Kevin R. Webster	2021	18
7	Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures Cell chemical biology ·Daniel A. Erlanson, Ben Davis, Wolfgang Jahnke	2018	90
8	Twenty years on: the impact of fragments on drug discovery Nature Reviews Drug Discovery ·Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard, Wolfgang Jahnke, Harren Jhoti Hit paper breakdown →	2016	684
9	Unexpected Effect of Proton Pump Inhibitors Circulation ·Yohannes T. Ghebremariam, Paea LePendu, Jerry C. Lee, Daniel A. Erlanson, Anna Slaviero, Nigam H. Shah, James Leiper, John P. Cooke	2013	194
10	Fragment-based lead discovery The biomedical & life sciences collection. ·Daniel A. Erlanson	2013	1
11	A Novel and Potent Inhibitor of Dimethylarginine Dimethylaminohydrolase: A Modulator of Cardiovascular Nitric Oxide Journal of Pharmacology and Experimental Therapeutics ·Yohannes T. Ghebremariam, Daniel A. Erlanson, John P. Cooke	2013	30
12	Development of a Dimethylarginine Dimethylaminohydrolase (DDAH) Assay for High-Throughput Chemical Screening SLAS DISCOVERY ·Yohannes T. Ghebremariam, Daniel A. Erlanson, Keisuke Yamada, John P. Cooke	2012	19
13	Introduction to Fragment-Based Drug Discovery Topics in current chemistry ·Daniel A. Erlanson	2011	199
14	Fragment-based lead discovery: a chemical update Current Opinion in Biotechnology ·Daniel A. Erlanson	2006	108
15	Allosteric Inhibition of PTP1B Activity by Selective Modification of a Non-Active Site Cysteine Residue Biochemistry ·Stig K. Hansen, Mark T. Cancilla, Razita Najih Relyza, Tomohiro Nagano, Teresa C. Chen, Daniel A. Erlanson	2005	59
16	Allosteric inhibition of protein tyrosine phosphatase 1B Nature Structural & Molecular Biology ·Christian Wiesmann, Kenneth J. Barr, Tomohiro Nagano, Jiang Zhu, Daniel A. Erlanson, Shen Wang, Nareerat Chaikong, Min Zhong, Lisa J. Taylor, Mike Randal, Robert S. McDowell, Stig K. Hansen	2004	439
17	Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly Current Opinion in Chemical Biology ·Daniel A. Erlanson, Stig K. Hansen	2004	47
18	In situ assembly of enzyme inhibitors using extended tethering Nature Biotechnology ·Daniel A. Erlanson, Joni W. Lam, Christian Wiesmann, Tinh N. Luong, Robert L. Simmons, Warren L. DeLano, Ingrid Choong, Matthew Burdett, W. Michael Flanagan, Dennis Lee, Eric M. Gordon, Thomas O’Brien	2003	155
19	The leucine zipper domain controls the orientation of AP-1 in the NFAT·AP-1·DNA complex Chemistry & Biology ·Daniel A. Erlanson, Milan Chytil, Gregory L. Verdine	1996	99
20	Falling out of the fold: tumorigenic mutations and p53 Chemistry & Biology ·Daniel A. Erlanson, Gregory L. Verdine	1994	6

About Daniel A. Erlanson

Daniel A. Erlanson is a scholar working on Computational Theory and Mathematics, Organic Chemistry, Pharmaceutical Science, Pharmacology and Molecular Biology, having authored 50 papers that have together received 4.4k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (18 papers), Click Chemistry and Applications (15 papers), Chemical Synthesis and Analysis (12 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Pharmacogenetics and Drug Metabolism (4 papers), Pharmaceutical Economics and Policy (4 papers), Nitric Oxide and Endothelin Effects (3 papers) and DNA and Nucleic Acid Chemistry (3 papers). The work is most often cited by research in Computational Theory and Mathematics (1.2k citations), Molecular Biology (3.3k citations), Organic Chemistry (1.2k citations), Toxicology (136 citations) and Pharmacology (334 citations). Daniel A. Erlanson has collaborated with scholars based in United States, Switzerland and Netherlands. Frequent co-authors include Wolfgang Jahnke, Robert S. McDowell, Thomas O’Brien, James A. Wells, Andrew C. Braisted, Harren Jhoti, Roderick E. Hubbard, Stephen W. Fesik, Mike Randal and Ben Davis. Their work appears in journals such as Journal of Medicinal Chemistry, Proceedings of the National Academy of Sciences, Journal of the American Chemical Society, Nature Communications and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact